Clinical trials: Cutaneous Leishmaniasis
Cutaneous Leishmaniasis
High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus
The purpose of this study is to evaluate the therapeutic response to fluconazole in patients with cutaneous leishmaniasis caused by and L.(V.)guyanensis and L.(V.) braziliensis.
- Trial name
- NCT01953744
- Testing
- Fluconazole, Meglumine Antimoniate
- Where
- Brazil
- Volunteers
- 53 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Localized Cutaneous Leishmaniasis
A Clinical Trial to Investigate Efficacy, Safety and Pharmacokinetics (PK) of Two LXE408 Oral Regimens and Oral Miltefosine as Active Control in Participants Aged ≥ 18 Years Old With Localized Cutaneous Leishmaniasis in the Region of the Americas (AMR).
The purpose of this clinical trial is to measure efficacy, safety and pharmacokinetics (PK) of two LXE408 oral regimens and oral miltefosine tablets as active control in localized cutaneous leishmaniasis in the region of the…
- Trial name
- NCT06997159
- Testing
- LXE408, Miltefosine 50 MG Oral Capsule [Impavido]
- Where
- 5 sites in Brazil, Panama
- Volunteers
- 250 people
- Sponsor
- Drugs for Neglected Diseases
Localized Cutaneous Leishmaniasis
Low-dose Pentavalent Antimony Treatment of Cutaneous Leishmaniasis in Old Age Patients
This study was designed to evaluate the effect of low doses of pentavalent antimony (meglumine antimoniate) to treat cutaneous leishmaniasis ulcers in patients older than 65 years.
- Trial name
- Sbold (NCT00818818)
- Testing
- Meglumine antimoniate
- Where
- Brazil
- Volunteers
- 13 people
- Sponsor
- University of Brasilia
Cutaneous Leishmaniasis
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
The objectives of the study are to evaluate the safety and efficacy of open label treatment with WR 279,396 (topical paromomycin \& gentamicin) in patients with non-complicated, non-severe cutaneous leishmaniasis (CL).
- Trial name
- PAGELEC (NCT01988909)
- Testing
- WR 279,396
- Where
- 2 sites in France
- Volunteers
- 18 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Mucosal Leishmaniasis, Cutaneous Leishmaniasis
Miltefosine to Treat Mucocutaneous Leishmaniasis
The purpose of this Treatment Investigational New Drug application was to make miltefosine available for mucocutaneous leishmaniasis patients presenting in the United States.
- Trial name
- NCT01050907
- Testing
- Miltefosine
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Knight Therapeutics (USA) Inc
Leishmania Infantum Disease, Leishmaniasis, Visceral
LEISH-PED: Study on Leishmaniasis in Children
Leishmaniasis is an infection caused by Leishmania parasites. In children, it can affect the skin or internal organs. Diagnosis may be delayed because the signs and symptoms can be similar to those of other conditions.
- Conditions
- Leishmania Infantum Disease, Leishmaniasis, Visceral, Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous
- Trial name
- LEISH-PED (NCT07504757)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- Meyer Children's Hospital IRCCS
Treatment of Cutaneous Leishmaniasis in Brazil.
Trial of Miltefosine in Cutaneous Leishmaniasis (Brazil)
The hypothesis of this trial is that the therapeutic activity and safety of oral miltefosine in Brazilian patients with cutaneous leishmaniasis is similar or superior to the intravenous standard treatment (meglumine antimoniate …
- Trial name
- NCT00600548
- Testing
- Miltefosine., Meglumine antimoniate.
- Where
- 2 sites in Brazil
- Volunteers
- 180 people
- Sponsor
- Hospital Universitário Professor Edgard Santos
Cutaneous Leishmaniases
Spatial Analysis of Host-parasite Interactions in Cutaneous Leishmaniasis in Ethiopia
Cutaneous leishmaniasis manifestations range from self-healing localized skin ulcers/nodules to diffusely spread chronic lesions.
- Trial name
- SpatialCL (NCT05332093)
- Testing
- skin biopsy, venous blood sample (plasma, PBMC, WB), venous blood sample (HLA)
- Where
- Ethiopia
- Volunteers
- 92 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cutaneous Leishmaniasis
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
This study will test whether addition of imiquimod to standard antimony therapy provides a significant benefit in subjects with newly diagnosed cutaneous leishmaniasis.
- Trial name
- NCT00257530
- Testing
- Imiquimod
- Where
- 2 sites in Peru
- Volunteers
- 80 people
- Sponsor
- Drugs for Neglected Diseases
Leishmaniasis
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
The investigators will compare the common treatment for cutaneous leishmaniasis with intra-lesional Pentostam to fractional CO2 laser with topical application of Pentostam.
- Trial name
- NCT03009422
- Testing
- Local application pentostam, intra-lisional pentostam, fractional CO2 laser
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Cutaneous Leishmaniasis
Efficacy of Intra-lesional Injections of Glucantime Once a Week or Twice a Week in the Treatment of Anthroponotic Cutaneous Leishmaniasis (ACL)
Anthroponotic Cutaneous Leishmaniasis (ACL) is a parasitic disease caused by Leishmania tropica, pentavalent antimonials (sodium stibogluconate and meglumine antimoniate) have been used as a standard treatment for leishmaniasis…
- Trial name
- NCT04340128
- Testing
- Meglumine antimoniate
- Where
- Iran
- Sponsor
- Tehran University of Medical Sciences
Cutaneous Leishmaniasis
Pharmacokinetics of Miltefosine in Children and Adults
The purpose of this study is to determine the pharmacokinetics of miltefosine in children and adults with cutaneous leishmaniasis in plasma and intracellularly, and its relation with the parasitologic response.
- Trial name
- PK (NCT01462500)
- Testing
- Miltefosine
- Where
- Colombia
- Volunteers
- 60 people
- Sponsor
- Centro Internacional de Entrenamiento e Investigaciones Médicas
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute
Cutaneous Leishmaniases
Evaluation of Point-of-care Tests for the Diagnosis of Cutaneous Leishmaniasis in Afghanistan
New point-of-care (POC) tests are needed and assessing the performance of these tests for cutaneous leishmaniasis (CL) in Afghanistan may help increasing the number of CL patients with access to accurate diagnosis, and enable…
- Trial name
- CLeishPOCAFG (NCT03435419)
- Testing
- LoopampTM Leishmania Detection Kit, CL DetectTM Rapid Test
- Volunteers
- 274 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Mucosal Leishmaniasis
Treatment of Mucosal Bolivian Leishmaniasis
The purpose of this protocol is to conduct a randomized comparison of the efficacy and tolerance of miltefosine, LAMB, and pentavalent antimony for the treatment of mucosal leishmaniasis.
- Trial name
- NCT04799236
- Testing
- Group 1: Miltefosine, Group 2: Pentavalent Antimony, Group 3: Liposomal amphotericin B
- Where
- Bolivia
- Volunteers
- 120 people
- Sponsor
- Fundacion Nacional de Dermatologia
Cutaneous Leishmaniasis
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Cutaneous leishmaniasis is typically treated with the parenteral product pentavalent antimony. Miltefosine is an oral agent shown to be active for mucosal leishmaniasis due to L braziliensis in Bolivia and cutaneous leishmaniasis…
- Trial name
- NCT00233545
- Testing
- miltefosine, antimony
- Where
- Bolivia
- Volunteers
- 80 people
- Sponsor
- AB Foundation
Leishmaniasis, Cutaneous, Leishmaniasis
Ex Vivo Immunogenicity Screening of Vaccine Candidate Antigen Combinations in Ethiopian Patients With Leishmaniasis
This study assesses the immunoprevalence (presence of the induced T-cell response across different patients (and thus HLA types) of six prioritized IPX-derived Leishmania antigens, using Good Laboratory Practice-grade soluble…
- Conditions
- Leishmaniasis, Cutaneous, Leishmaniasis, Leishmaniasis, Visceral, Immunogenicity
- Trial name
- LEISHVAC (NCT07783243)
- Where
- 2 sites in Ethiopia
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Leishmaniasis, Cutaneous
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
Leishmaniasis is considered by the WHO as emerging and uncontrolled diseases. They are the second leading cause of death and the fourth leading cause of morbidity in tropical diseases.
- Trial name
- Asymptoleish (NCT03303898)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Nice
Cutaneous Leishmaniases
Combination, Miltefosine Monotherapy for Cutaneous Leishmaniasis in New World
This study evaluates if the combination of thermotherapy (one application, 50⁰C for 30") and 3 weeks of miltefosine is safe and have a comparable cure rate with the current recommended first line treatments comprising meglumine…
- Trial name
- NCT04515186
- Testing
- Meglumine Antimoniate, Miltefosine, Thermotherapy machine
- Where
- 6 sites in Bolivia, Brazil and 2 more
- Volunteers
- 184 people
- Sponsor
- Drugs for Neglected Diseases
Leishmaniasis, Cutaneous
Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis.
Cutaneous Leishmaniasis (CL) is a parasitic disease caused by more than 15 different species of the protozoan parasite Leishmania.
- Trial name
- Curaleish (NCT04072874)
- Testing
- Experimental topical (Curaleish Topical)
- Where
- Colombia
- Sponsor
- Universidad de Antioquia